FDA has announced it has expanded the approved use of Humira (adalimumab), manufactured by Abbott Laboratories, to include treatment of moderate-to-severe ulcerative colitis in adults, according to a ...

The FDA recently designated Yuflyma as "interchangeable" with the popular biologic Humira for the treatment of Crohn's disease and ulcerative colitis, two types of inflammatory bowel disease (IBD), ...

Biologics in IBD: More Thoughtful Use Could Improve Outcomes The marketplace introduction of infliximab for the treatment of IBD did not reduce hospitalization or surgery rates in a large population ...

April 11 (Reuters) - Humira, the best-selling arthritis drug that forms the cornerstone of Abbott Laboratories' pharmaceutical business, has been approved in Europe for ulcerative colitis, the U.S.

Does CRC Risk in IBD Extend to Close Family Members? Close relatives of people with IBD are not at increased risk for CRC, strengthening the theory that it's the inflammation or atypia of the colon ...

WASHINGTON, Aug 24 (Reuters) - Abbott Laboratories Inc may need to conduct additional trials of Humira to prove the blockbuster drug helps patients with ulcerative colitis, U.S. drug reviewers said on ...